Revvity (RVTY) AI Stock Analysis

• Market Cap: $11.14B
• Dividend Yield: 0.32%
• Average Volume (3M): 1.30M
• Price to Earnings (P/E): 40.1
• Beta (1Y): 0.65
• Revenue Growth: 3.33%
• EPS Growth: N/A
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.18
• Shares Outstanding: 117,869,660
• 10 Day Avg. Volume: 2,007,900
• 30 Day Avg. Volume: 1,304,361
• PEG Ratio: 92.83
• Price to Book (P/B): 1.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 22.20
• Enterprise Value/Market Cap: 1.21
• Enterprise Value/Revenue: 1.49
• Enterprise Value/Gross Profit: 13.25
• Enterprise Value/Ebitda: 8.57
• 1Y Price Target: $114.58
• Price Target Upside: 30.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 12

• Rating: 63 Neutral
• Price Target: $101.00 ▲(14.90%Upside)

Revvity's stock score reflects a balanced financial outlook with moderate strengths in cash flow and innovation. The key risks include overvaluation concerns and external challenges in specific segments. Despite these, the company's strategic initiatives and robust cash flow management provide a solid foundation for future performance.

Positive Factors

Cost Management

RVTY is taking additional cost actions to help offset margin pressures, allowing for potential margin expansion.

Portfolio Resilience

Revvity, Inc.'s transformed portfolio is expected to be resilient through ongoing market turbulence.

Software Growth

Software, which represents 7% of revenue, grew approximately 30%, driving significant growth in the company.

Negative Factors

China Policy Changes

China implemented changes to hospital lab reimbursement, impacting high-margin multiplex tests and reducing confidence in the business outlook.

Revenue and EPS Guidance Cut

RVTY shares traded lower due to a guidance cut, with both organic growth and EPS expectations lowered.

Tariff Headwinds

Life Sciences products face high China tariffs, requiring supply chain rework and posing a challenge to top-line growth.

Revvity Business Overview & Revenue Model

Company Description

Revvity (RVTY) is a diversified company operating in various sectors, including healthcare, industrial, and consumer markets. The company offers a wide range of products and services designed to improve efficiency and innovation across its target industries. Revvity is committed to providing high-quality solutions that address the unique challenges faced by its clients, leveraging advanced technology and expertise to deliver superior outcomes.

How the Company Makes Money

Revvity generates revenue through the sale of its diverse portfolio of products and services. The company's key revenue streams include the manufacturing and distribution of healthcare equipment, industrial machinery, and consumer products. Additionally, Revvity engages in strategic partnerships and collaborations that enhance its market presence and drive sales growth. By focusing on innovation and customer satisfaction, Revvity maintains a competitive edge, ensuring steady income from both longstanding and new business relationships.

Revvity Financial Statement Overview

Summary

Revvity presents a stable financial profile with steady margins and a solid balance sheet. Despite some pressure on profitability and revenue growth, the company maintains strong operational cash flows and a healthy equity base.

Income Statement

Revvity's income statement shows moderate performance with a positive Gross Profit Margin of 55.93% and a decent Net Profit Margin of 10.19% for TTM. However, the company is facing challenges in revenue growth, with a slight increase of 1.58% from the previous year. EBIT Margin is satisfactory at 13.58%, although EBITDA Margin has decreased to 25.68% from last year's 30.50%.

Balance Sheet

The balance sheet reveals a stable financial position with a Debt-to-Equity Ratio of 0.45, indicating manageable leverage. Return on Equity (ROE) is moderate at 3.77% for TTM, reflecting a decrease in profitability compared to previous years. The Equity Ratio stands at a robust 61.11%, suggesting strong financial stability.

Cash Flow

Cash flow from operations is healthy, with an Operating Cash Flow to Net Income Ratio of 2.07, indicating efficient conversion of income into cash. However, Free Cash Flow declined by 6.05% from the previous year, and the Free Cash Flow to Net Income Ratio is 1.78, suggesting room for improvement in cash generation relative to income.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.76B	2.75B	3.31B	3.83B	2.66B
Gross Profit	1.54B	1.54B	1.99B	2.43B	1.74B
EBITDA	840.25M	713.56M	1.18B	1.73B	1.20B
Net Income	270.38M	693.09M	569.18M	943.16M	727.89M
Balance Sheet
Total Assets	12.39B	13.56B	14.13B	15.00B	7.96B
Cash, Cash Equivalents and Short-Term Investments	1.16B	1.60B	454.36M	603.32M	402.04M
Total Debt	3.33B	4.07B	4.60B	5.16B	2.22B
Total Liabilities	4.73B	5.69B	6.75B	7.86B	4.22B
Stockholders Equity	7.67B	7.87B	7.38B	7.14B	3.74B
Cash Flow
Free Cash Flow	541.65M	9.90M	594.18M	1.32B	814.67M
Operating Cash Flow	628.30M	91.27M	679.81M	1.41B	892.18M
Investing Cash Flow	776.16M	1.31B	-132.85M	-4.11B	-504.50M
Financing Cash Flow	-1.13B	-947.12M	-661.80M	2.94B	-202.87M

Revvity Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 87.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVTY, the sentiment is Negative. The current price of 87.9 is below the 20-day moving average (MA) of 97.11, below the 50-day MA of 95.22, and below the 200-day MA of 107.06, indicating a bearish trend. The MACD of -0.94 indicates Positive momentum. The RSI at 37.48 is Neutral, neither overbought nor oversold. The STOCH value of 14.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVTY.

Revvity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDP	78 Outperform	$12.00B	31.77	89.38%	―	9.94%	25.30%
QGEN	75 Outperform	$10.68B	118.21	2.67%	2.54%	3.31%	-72.63%
DGX	71 Outperform	$18.72B	20.02	13.65%	1.85%	12.58%	13.00%
NTRA	64 Neutral	$18.55B	―	-18.66%	―	51.50%	53.23%
RVTY	63 Neutral	$11.14B	40.06	3.70%	0.32%	3.33%	―
ILMN	55 Neutral	$16.26B	―	-23.82%	―	-3.47%	25.55%
Sector *	51 Neutral	$7.30B	0.27	-62.71%	2.44%	15.02%	0.60%

Revvity Corporate Events

Revvity to Announce Q4 and Full-Year 2024 Results

Revvity announced it will release its fourth quarter and full-year 2024 financial results on January 31, 2025, followed by a conference call led by CEO Prahlad Singh and CFO Max Krakowiak. The company expects fourth-quarter revenue growth of approximately 5% to 6% and anticipates meeting or exceeding its full-year 2024 adjusted earnings per share guidance. Revvity is also set to present at the J.P. Morgan Healthcare Conference, where it will discuss these financial results and future projections, reflecting its strong positioning in the healthcare industry.